ACEi reduces hypertension-induced hyperinflammation in COVID-19

Antihypertensive therapy, particularly with the use of an angiotensin-converting enzyme inhibitor, improves outcomes in patients with hypertension and SARS-CoV-2 infection, who are susceptible to hyperinflammation and severe outcomes with COVID-19.

Detalles Bibliográficos
Autor principal: Lim, Gregory B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Research Highlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812557/
https://www.ncbi.nlm.nih.gov/pubmed/33462417
http://dx.doi.org/10.1038/s41569-021-00512-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7812557/
https://www.ncbi.nlm.nih.gov/pubmed/33462417
http://dx.doi.org/10.1038/s41569-021-00512-9

Ejemplares similares